- Home
- HOOK vs IRIX Comparison
HOOK vs IRIX Comparison
Compare HOOK & IRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOOK
- IRIX
- Stock Information
- Founded
- HOOK 2011
- IRIX 1989
- Country
- HOOK United States
- IRIX United States
- Employees
- HOOK N/A
- IRIX N/A
- Industry
- HOOK Biotechnology: Pharmaceutical Preparations
- IRIX Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- HOOK Health Care
- IRIX Health Care
- Exchange
- HOOK Nasdaq
- IRIX Nasdaq
- Market Cap
- HOOK 15.3M
- IRIX 16.5M
- IPO Year
- HOOK 2019
- IRIX 1996
- Fundamental
- Price
- HOOK $1.20
- IRIX $1.00
- Analyst Decision
- HOOK Buy
- IRIX
- Analyst Count
- HOOK 4
- IRIX 0
- Target Price
- HOOK $10.67
- IRIX N/A
- AVG Volume (30 Days)
- HOOK 67.1K
- IRIX 67.6K
- Earning Date
- HOOK 08-07-2025
- IRIX 08-07-2025
- Dividend Yield
- HOOK N/A
- IRIX N/A
- EPS Growth
- HOOK N/A
- IRIX N/A
- EPS
- HOOK N/A
- IRIX N/A
- Revenue
- HOOK $9,351,000.00
- IRIX $48,804,000.00
- Revenue This Year
- HOOK N/A
- IRIX $9.61
- Revenue Next Year
- HOOK N/A
- IRIX N/A
- P/E Ratio
- HOOK N/A
- IRIX N/A
- Revenue Growth
- HOOK N/A
- IRIX N/A
- 52 Week Low
- HOOK $0.72
- IRIX $0.78
- 52 Week High
- HOOK $6.77
- IRIX $2.41
- Technical
- Relative Strength Index (RSI)
- HOOK 39.18
- IRIX 57.40
- Support Level
- HOOK $1.13
- IRIX $0.92
- Resistance Level
- HOOK $1.35
- IRIX $1.01
- Average True Range (ATR)
- HOOK 0.06
- IRIX 0.05
- MACD
- HOOK -0.01
- IRIX 0.01
- Stochastic Oscillator
- HOOK 40.64
- IRIX 92.79
About HOOK HOOKIPA Pharma Inc.
HOOKIPA Pharma Inc is a clinical-stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. Its oncology portfolio targets oncoviral cancer antigens and next-generation antigens and includes two primary programs in development: eseba-vec (formerly HB-200) and HB-700. Eseba-vec is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers. It also develops infectious disease therapies in partnership with other companies. Its Hepatitis B (HBV) program, HB-400, and Human Immunodeficiency Virus (HIV) program, HB-500, are being developed in partnership with Gilead.
About IRIX IRIDEX Corporation
IRIDEX Corp is involved in the business of developing, manufacturing, and marketing laser-based medical systems, delivery devices, and consumable instrumentation for ophthalmology. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, services, and support activities. The geographical segments of the company include the United States, which drives maximum revenue, Europe, and the Americas, excluding the U.S. and Asia/Pacific Rim.